DDrare: Database of Drug Development for Rare Diseases

75. クッシング病
［臨床試験数：191，薬物数：172（DrugBank：48），標的遺伝子数：61，標的パスウェイ数：121］

Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)-4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4-(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; (R)-(1-(4-FLUOROPHENYL)-6-((1-METHYL-1H-PYRAZOL-4-YL)SULFONYL)4,4A,5,6,7,8-HEXAHYDRO-1H-PYRAZOLO[3,4-G]ISOQUINOLIN-4A-YL)(4(TRIFLUOROMETHYL)PYRIDIN-2-YL)METHANONE; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one; 18F-DOPA; 1H-Pyrazol; 2S,4R-(-)-ketoconazole; 2S,4R-(-)-ketoconazole, levoketoconazole; ATR-101; AZD4017; AZD4017 and prednisolone; Abiraterone; Abiraterone Acetate; Acetate; Acthrel; Bexarotene; CABERGOLINE; CABERGOLINE TEVA; CI-984; CIALIS - 20 MG 2 COMPRESSE RIVESTITE CON FILM IN BLISTER USO ORALE; COR-003; CORT125134; Cabergoline; Calcium; Calcium carbonate; Carbonate; Corticotropin; Corticotropin-releasing hormone; Cushing's syndrome confirmation; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D) Trp-Ly di-aspartate; Cyclo ((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Ly di-aspartate; Cyclo((diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe) di-aspartate; Cyclo(diaminoethyl-carbamate)HyPro-Phg-(D)Trp-Lys-Tyr(Bzl)-Phe); DDAVP; DOSTINEX; Device: IPC; Device: continuous glucose monitoring; Dexamethasone; Diagnostic Test: 24-hour Urine test; Diagnostic Test: Blood test; Diagnostic Test: CT scan; Diagnostic Test: Dexamethasone test; Diagnostic Test: MRI; Diagnostic Test: Saliva swab; Dostinex; Dotatate; Eplerenone; Gefitinib; Genotropin 12mg; Genotropin 5.3mg; Genotropin Miniqu; Genotropin Miniquick 0.2mg; Genotropin Miniquick 0.4mg; Genotropin Miniquick 0.6mg; Genotropin Miniquick 0.8mg; Genotropin Miniquick 1.0mg; Genotropin Miniquick 1.2mg; Glucocorticoids; Glucophage (metformin); Glucose; HRA052015; HRA052015 (mifepristone); Hydrocortisone; Hypro; Insulin; KETOCONAZOLE; Ketoconazole; L0006CP03A; LA; LCI699; LCI699, 1 mg; LCI699, 10 mg; LCI699, 20 mg; LCI699, 5 mg; LMWH/Rivaroxaban; Lapatinib; Levoketoconazole; Levoketozonazole; Liqourice; Liraglutide; METYRAPONE; MIFEPRISTONE; Matyrapone; Metformin; Methionine; Metopirone; Metopirone 250 mg capsules; Metopirone 250 mg capsules/Cormeto; Metyrapone; Mifedren; Mifepristone; NIZORAL; Nevanimibe; Nevanimibe hydrochloride; Nizoral; OROCAL; OSILODROSTAT; OSTEOPOR; Octreotide; Osilodrostat; Osilodrostat 10mg; Osilodrostat 1mg; Osilodrostat 20mg; Osilodrostat 5mg; Ossein hydroxyapatite; Other: Control; Other: Hydrocortisone; Other: Obese; Other: [11C]-Methionine PET/MRI; Ovine Corticotropin-Releasing Hormone (oCRH); PASIREOTIDE; PASIREOTIDE DIASPARTATE; PASIREOTIDE PAMOATE; Pasireotida; Pasireotida 300; Pasireotida 600; Pasireotida 900; Pasireotide; Pasireotide 0.3mg; Pasireotide 0.6 MG/ML; Pasireotide 0.6mg; Pasireotide 0.9 mg; Pasireotide 20mg; Pasireotide 40mg; Pasireotide 60mg; Pasireotide LAR; Pasireotide pamoate; Pasireotide s.c.; Pasireotide sub-cutaneous; Pasireotide with or without cabergoline; Pasireotode; Pentetreotide; Phe; Prednisolone; Procedure: Hypercortisolism; Procedure: Lateral transperitoneal LA; Procedure: Posterior RA; R-roscovitine; RVG 08938; RVG 15375; RVG 18236; Radiation: DOTATATE PET-CT; Radiation: F-DOPA PET CT; Relacorilant; Rivaroxaban; Rosiglitazone; Rosiglitazone maleate; SIGNIFOR; SOM230; SOM230 300µg; SOM230 600µg; SOM230 900µg; SOM230 LAR; SOM230 LAR 10 mg; SOM230 LAR 30 mg; SOM230 LAR, 20 mg; SOM230 s.c.; SOM230, 300micrograms; SOM230, 600 micrograms; SOM230, 900 micrograms; SOM230B; SOMATROPIN; Seliciclib; Signifor; Sitagliptin; Somatropin; Tadalafil; Tretinoin; Trp; Tyr; Valsartan; Vorinostat

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2014-000162-22-PL (EUCTR)	27/07/2016	21/04/2016	Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period	Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT	Treatment of Cushing’s syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Laboratoire HRA Pharma	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	55	Phase 4	Hungary;Belgium;Spain;Poland;Romania;Turkey;Germany;Italy
2	EUCTR2014-000162-22-HU (EUCTR)	06/10/2015	08/07/2015	Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period	Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT	Treatment of Cushing’s syndrome MedDRA version: 18.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Product Name: metyrapone INN or Proposed INN: METYRAPONE	Laboratoire HRA Pharma	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 4	Hungary;Spain;Poland;Belgium;Germany;Italy
3	EUCTR2014-000162-22-DE (EUCTR)	04/05/2015	30/10/2014	Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period	Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT	Treatment of Cushing’s syndrome MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Metopirone 250 mg capsules Product Name: metyrapone INN or Proposed INN: METYRAPONE	Laboratoire HRA Pharma	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 4	Hungary;Poland;Romania;Germany;Italy;Spain;Belgium;Turkey
4	NCT02297945 (ClinicalTrials.gov)	April 2015	19/11/2014	Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome	Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks	Cushing's Syndrome	Drug: metyrapone	HRA Pharma	NULL	Completed	18 Years	N/A	All	50	Phase 3	Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey
5	EUCTR2014-000162-22-IT (EUCTR)	19/03/2015	25/11/2014	Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period	Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT	Treatment of Cushing’s syndrome MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Metopirone 250 mg capsules/Cormeto Product Name: metyrapone INN or Proposed INN: METYRAPONE	Laboratoire HRA Pharma	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 4	United States;Hungary;Spain;Poland;Belgium;Germany;Switzerland;Italy;Sweden
No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
6	EUCTR2014-000162-22-BE (EUCTR)	11/03/2015	04/12/2014	Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period	Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT	Treatment of Cushing’s syndrome MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Metopirone 250 mg capsules Product Name: metyrapone	Laboratoire HRA Pharma	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 4	United States;Hungary;Spain;Poland;Belgium;Germany;Switzerland;Italy;Sweden
7	EUCTR2014-000162-22-ES (EUCTR)	23/02/2015	16/01/2015	Study to assess the effects of metyrapone in patients with Cushing?s syndrome during a 12-week treatment period	Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing?s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT	Treatment of Cushing?s syndrome MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Metopirone 250 mg capsules Product Name: metyrapone INN or Proposed INN: METYRAPONE	Laboratoire HRA Pharma	NULL	Not Recruiting			Female: yes Male: yes	70	Phase 3	United States;Hungary;Poland;Belgium;Spain;Germany;Italy;Switzerland;Sweden
8	EUCTR2013-002063-26-IT (EUCTR)	08/09/2013	23/07/2013	A trial with Metyrapone in Cushing's syndrome	A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with ACTH-independent Cushing’s syndrome due to adrenal adenoma. - METYX01	Cushing's syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Matyrapone Product Name: Metyrapone Product Code: Metyrapone	S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	15	Phase 2	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2014-000162-22-PL
(EUCTR)

27/07/2016

21/04/2016

Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period

Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing’s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT

Treatment of Cushing’s syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders ;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Laboratoire HRA Pharma

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 4

Hungary;Belgium;Spain;Poland;Romania;Turkey;Germany;Italy

EUCTR2014-000162-22-HU
(EUCTR)

06/10/2015

08/07/2015

Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period

Treatment of Cushing’s syndrome
MedDRA version: 18.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Product Name: metyrapone
INN or Proposed INN: METYRAPONE

Laboratoire HRA Pharma

NULL

Not Recruiting

Female: yes
Male: yes

Phase 4

Hungary;Spain;Poland;Belgium;Germany;Italy

EUCTR2014-000162-22-DE
(EUCTR)

04/05/2015

30/10/2014

Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period

Treatment of Cushing’s syndrome
MedDRA version: 20.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Trade Name: Metopirone 250 mg capsules
Product Name: metyrapone
INN or Proposed INN: METYRAPONE

Laboratoire HRA Pharma

NULL

Not Recruiting

Female: yes
Male: yes

Phase 4

Hungary;Poland;Romania;Germany;Italy;Spain;Belgium;Turkey

NCT02297945
(ClinicalTrials.gov)

April 2015

19/11/2014

Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome

Prospective, Single Arm, Open-label, Multicenter, International Study to Assess the Effects of Metyrapone in Patients With Endogenous Cushing's Syndrome During a 12-week Treatment Period Followed by an Extension Period of 24 Weeks

Cushing's Syndrome

Drug: metyrapone

HRA Pharma

NULL

Completed

18 Years

N/A

All

Phase 3

Belgium;Germany;Hungary;Italy;Poland;Romania;Spain;Turkey

EUCTR2014-000162-22-IT
(EUCTR)

19/03/2015

25/11/2014

Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period

Treatment of Cushing’s syndrome
MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Trade Name: Metopirone 250 mg capsules/Cormeto
Product Name: metyrapone
INN or Proposed INN: METYRAPONE

Laboratoire HRA Pharma

NULL

Not Recruiting

Female: yes
Male: yes

Phase 4

United States;Hungary;Spain;Poland;Belgium;Germany;Switzerland;Italy;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2014-000162-22-BE
(EUCTR)

11/03/2015

04/12/2014

Study to assess the effects of metyrapone in patients with Cushing’s syndrome during a 12-week treatment period

Trade Name: Metopirone 250 mg capsules
Product Name: metyrapone

Laboratoire HRA Pharma

NULL

Not Recruiting

Female: yes
Male: yes

Phase 4

United States;Hungary;Spain;Poland;Belgium;Germany;Switzerland;Italy;Sweden

EUCTR2014-000162-22-ES
(EUCTR)

23/02/2015

16/01/2015

Study to assess the effects of metyrapone in patients with Cushing?s syndrome during a 12-week treatment period

Prospective, single arm, open-label, multicenter, international study to assess the effects of metyrapone in patients with endogenous Cushing?s syndrome during a 12-week treatment period followed by an extension period of 24 weeks. - PROMPT

Treatment of Cushing?s syndrome
MedDRA version: 17.1;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Trade Name: Metopirone 250 mg capsules
Product Name: metyrapone
INN or Proposed INN: METYRAPONE

Laboratoire HRA Pharma

NULL

Not Recruiting

Female: yes
Male: yes

Phase 3

United States;Hungary;Poland;Belgium;Spain;Germany;Italy;Switzerland;Sweden

EUCTR2013-002063-26-IT
(EUCTR)

08/09/2013

23/07/2013

A trial with Metyrapone in Cushing's syndrome

A prospective open-label Phase 2 study of METYRAPONE as a preoperative treatment in patients with ACTH-independent Cushing’s syndrome due to adrenal adenoma. - METYX01

Cushing's syndrome;Therapeutic area: Diseases [C] - Hormonal diseases [C19]

Trade Name: Matyrapone
Product Name: Metyrapone
Product Code: Metyrapone

S.C.D.U. MEDICINA INTERNA 1 Ospedale San Luigi Orbassano

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 2

Italy